Can insulin signaling pathways be targeted to transport Aβ out of the brain?
暂无分享,去创建一个
[1] F. Bilotta,et al. Insulin and the Brain , 2017, Journal of intensive care medicine.
[2] Yixue Xue,et al. Effects of insulin combined with idebenone on blood–brain barrier permeability in diabetic rats , 2015, Journal of neuroscience research.
[3] Arthur W. Toga,et al. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.
[4] M. Roden,et al. Effects of Intranasal Insulin on Hepatic Fat Accumulation and Energy Metabolism in Humans , 2015, Diabetes.
[5] B. Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015 .
[6] A. Convit,et al. Cerebral Perfusion in Insulin Resistance and Type 2 Diabetes , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] F. Calon,et al. Human Apolipoprotein E ε4 Expression Impairs Cerebral Vascularization and Blood—Brain Barrier Function in Mice , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] Xiao-dong Liu,et al. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances , 2014, Front. Pharmacol..
[9] Maiken Nedergaard,et al. Impairment of paravascular clearance pathways in the aging brain , 2014, Annals of neurology.
[10] R. Bateman,et al. Amyloid‐β efflux from the central nervous system into the plasma , 2014, Annals of neurology.
[11] B. Strooper,et al. Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.
[12] G. Lewis,et al. Intranasal Insulin Suppresses Endogenous Glucose Production in Humans Compared With Placebo in the Presence of Similar Venous Insulin Concentrations , 2014, Diabetes.
[13] M. Garcia-Alloza,et al. Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice , 2014, Psychoneuroendocrinology.
[14] K. Blennow,et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.
[15] B. Vissel,et al. Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease , 2014, Acta neuropathologica communications.
[16] M. Morris,et al. Dietary fat composition and dementia risk , 2014, Neurobiology of Aging.
[17] M. Ihara,et al. New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy , 2014, Front. Aging Neurosci..
[18] H. Hou,et al. Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice* , 2014, The Journal of Biological Chemistry.
[19] E. Mormino. The Relevance of Beta-Amyloid on Markers of Alzheimer’s Disease in Clinically Normal Individuals and Factors That Influence These Associations , 2014, Neuropsychology Review.
[20] R. Hammer,et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow , 2014, Molecular Neurodegeneration.
[21] Michèle Desjardins,et al. Aging-related differences in cerebral capillary blood flow in anesthetized rats , 2014, Neurobiology of Aging.
[22] P. Scheltens,et al. Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes , 2014, Diabetologia.
[23] A. Marette,et al. INSULIN REVERSES THE HIGH FAT DIET-INDUCED INCREASE IN BRAIN Aβ AND IMPROVES MEMORY IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.
[24] C. Kahn,et al. Insulin Action in Brain Regulates Systemic Metabolism and Brain Function , 2014, Diabetes.
[25] S. Ferreira,et al. Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease , 2014, Diabetes.
[26] Christian-Alexandre Castellano,et al. Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. , 2014, American journal of physiology. Endocrinology and metabolism.
[27] F. Calon,et al. Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease , 2014, Neuropharmacology.
[28] F. Calon,et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2 , 2014, Journal of neurochemistry.
[29] René Westerhausen,et al. Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation , 2014, Human brain mapping.
[30] M. Sabbagh,et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease , 2014, Neurology.
[31] Steven H. Liang,et al. Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. , 2014, Journal of labelled compounds & radiopharmaceuticals.
[32] C. Wellington,et al. High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. , 2014, Cell metabolism.
[33] E. Giralt,et al. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease , 2014, Nature Communications.
[34] M. O. Olde Rikkert,et al. Assessment of dynamic cerebral autoregulation and cerebrovascular CO2 reactivity in ageing by measurements of cerebral blood flow and cortical oxygenation , 2014, Experimental physiology.
[35] M. Schubert,et al. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. , 2014, CNS & neurological disorders drug targets.
[36] Kelly A. Tennant,et al. Diabetes Augments In Vivo Microvascular Blood Flow Dynamics after Stroke , 2013, The Journal of Neuroscience.
[37] Jean-Philippe Michaud,et al. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. , 2013, Cell reports.
[38] C. Pike,et al. Sex-Specific Effects of High Fat Diet on Indices of Metabolic Syndrome in 3xTg-AD Mice: Implications for Alzheimer's Disease , 2013, PloS one.
[39] Daniel J. R. Christensen,et al. Sleep Drives Metabolite Clearance from the Adult Brain , 2013, Science.
[40] P. Barberger‐Gateau,et al. Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline , 2013, Proceedings of the Nutrition Society.
[41] S. Shimohama,et al. Continuation of Exercise Is Necessary to Inhibit High Fat Diet-Induced β-Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice , 2013, PloS one.
[42] William A Banks,et al. Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[43] E. Siemers,et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.
[44] G. Landreth,et al. Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.
[45] B. Courten,et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects , 2013, Amino Acids.
[46] Johannes Kornhuber,et al. The influence of insulin infusion on the metabolism of amyloid β peptides in plasma , 2013, Alzheimer's & Dementia.
[47] J. Nicolazzo,et al. Altered Brain Uptake of Therapeutics in a Triple Transgenic Mouse Model of Alzheimer’s Disease , 2013, Pharmaceutical Research.
[48] Tammie L. S. Benzinger,et al. Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers , 2013, Science Translational Medicine.
[49] C. Hölscher,et al. Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence , 2013, CNS Drugs.
[50] Francis Eustache,et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.
[51] K. Mullane,et al. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.
[52] J. Ghersi-Egea,et al. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. , 2013, Molecular pharmaceutics.
[53] M. Krams,et al. 2012: A watershed year for Alzheimer’s disease research , 2013, The journal of nutrition, health & aging.
[54] K. Park,et al. Altered APP Processing in Insulin-Resistant Conditions Is Mediated by Autophagosome Accumulation via the Inhibition of Mammalian Target of Rapamycin Pathway , 2012, Diabetes.
[55] Y. Stern. Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.
[56] W. Banks,et al. Insulin in the brain: there and back again. , 2012, Pharmacology & therapeutics.
[57] B. Zlokovic,et al. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[58] Huadong Zhou,et al. Immunotherapy for Alzheimer disease—the challenge of adverse effects , 2012, Nature Reviews Neurology.
[59] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[60] Berislav V. Zlokovic,et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.
[61] Y. Reijmer,et al. Cerebral haemodynamics, cognition and brain volumes in patients with type 2 diabetes. , 2012, Journal of diabetes and its complications.
[62] D. Holtzman,et al. Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling , 2012, Molecular Neurodegeneration.
[63] S. Watson,et al. A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control , 2012, Diabetes.
[64] J. Schneider,et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.
[65] F. Tarazi,et al. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. , 2012, Pharmacology & therapeutics.
[66] I. Torres-Aleman,et al. The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.
[67] Hubert Preissl,et al. Differential effects of intranasal insulin and caffeine on cerebral blood flow , 2012, Human brain mapping.
[68] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[69] D. Alsop,et al. Adhesion Molecules, Altered Vasoreactivity, and Brain Atrophy in Type 2 Diabetes , 2011, Diabetes Care.
[70] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[71] D. Bennett,et al. Accumulation of Transactive Response DNA Binding Protein 43 in Mild Cognitive Impairment and Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.
[72] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[73] D. Selkoe,et al. Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.
[74] H. Preissl,et al. Insulin sensitivity of the human brain. , 2011, Diabetes research and clinical practice.
[75] K. Niswender. Basal Insulin: Physiology, Pharmacology, and Clinical Implications , 2011, Postgraduate medicine.
[76] Saeid Taheri,et al. Quantitative measurement of blood‐brain barrier permeability in human using dynamic contrast‐enhanced MRI with fast T1 mapping , 2011, Magnetic resonance in medicine.
[77] D. H. Lee,et al. Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[78] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[79] W. Pardridge. Drug transport in brain via the cerebrospinal fluid , 2011, Fluids and Barriers of the CNS.
[80] A. Nordberg,et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease , 2010, Brain : a journal of neurology.
[81] Toshiharu Suzuki,et al. Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain , 2010, Molecular Neurodegeneration.
[82] F. Calon,et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model , 2010, Neurobiology of Aging.
[83] C. Wellington,et al. ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice* , 2010, The Journal of Biological Chemistry.
[84] D. Holtzman,et al. Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.
[85] F. Domoki,et al. Cerebrovascular Responses to Insulin in Rats , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[86] Keith A. Johnson,et al. Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.
[87] M. Morris. The role of nutrition in Alzheimer’s disease: epidemiological evidence , 2009, European journal of neurology.
[88] Charles D. Smith,et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.
[89] P. Talmud,et al. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. , 2009, Atherosclerosis.
[90] Y. Xia,et al. Downregulation of LPR1 at the blood–brain barrier in streptozotocin-induced diabetic mice , 2009, Neuropharmacology.
[91] S. Cazaubon,et al. The blood-brain barrier in brain homeostasis and neurological diseases. , 2009, Biochimica et biophysica acta.
[92] I. Romero,et al. P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[93] F. LaFerla,et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease , 2009, Neuropharmacology.
[94] Joanna M. Wardlaw,et al. Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis , 2009, Neurobiology of Aging.
[95] R. Deane,et al. Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .
[96] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[97] M. Stoeckli,et al. Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.
[98] Miles C. Miller,et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease , 2008, Brain Research.
[99] J. Born,et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders , 2008, Regulatory Peptides.
[100] H. Kroemer,et al. MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier , 2007, Brain pathology.
[101] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[102] L. Mucke,et al. 100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.
[103] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[104] E. Golob,et al. Vascular volume and blood‐brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls , 2006, Journal of magnetic resonance imaging : JMRI.
[105] Miles C. Miller,et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease , 2006, Acta Neuropathologica.
[106] David M Holtzman,et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.
[107] W. Pan,et al. Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. , 2006, Endocrinology.
[108] M. Reger,et al. Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease , 2006, Neurology.
[109] G. Schellenberg,et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.
[110] V. Perry,et al. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. , 2006, Journal of theoretical biology.
[111] L. Fratiglioni,et al. Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.
[112] A. Fagan,et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.
[113] D. Stern,et al. Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.
[114] Jullie W Pan,et al. Human Cerebral Blood Flow and Metabolism in Acute Insulin-Induced Hypoglycemia , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[115] David W. Smith,et al. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor , 2005, Journal of Pharmacology and Experimental Therapeutics.
[116] R. Deane,et al. RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.
[117] T. Terasaki,et al. Brain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain , 2004, The Journal of Neuroscience.
[118] Hyoung-Gon Lee,et al. Lessons from the AN 1792 Alzheimer vaccine: lest we forget , 2004, Neurobiology of Aging.
[119] Patrick R Hof,et al. Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[120] William A Banks,et al. The source of cerebral insulin. , 2004, European journal of pharmacology.
[121] Ronald C Petersen,et al. Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.
[122] G. Alexander,et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[123] Keith A. Johnson,et al. Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.
[124] D. Holtzman,et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.
[125] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[126] S. Asthana,et al. Insulin increases CSF Aβ42 levels in normal older adults , 2003, Neurology.
[127] S. D. Preston,et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.
[128] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[129] Jan Born,et al. Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.
[130] D. Selkoe. Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.
[131] A. Kastin,et al. Glucose and Insulin Increase the Transport of Leptin through the Blood-Brain Barrier in Normal Mice but Not in Streptozotocin-Diabetic Mice , 2001, Neuroendocrinology.
[132] A. Schmidt,et al. The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.
[133] R. Egleton,et al. Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. , 2000, The Journal of pharmacology and experimental therapeutics.
[134] P. S. St George-Hyslop. Genetic Factors in the Genesis of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.
[135] M. Smith,et al. Amyloid-β junkies , 2000, The Lancet.
[136] O B Paulson,et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. , 1999, Diabetes.
[137] W. Banks,et al. Uptake and degradation of blood-borne insulin by the olfactory bulb , 1999, Peptides.
[138] K. Blennow,et al. A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.
[139] B. Greenberg,et al. Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester , 1998, The Journal of Neuroscience.
[140] W. Banks,et al. Selective, Physiological Transport of Insulin Across the Blood-Brain Barrier: Novel Demonstration by Species-Specific Radioimmunoassays , 1997, Peptides.
[141] W. Banks,et al. Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin , 1997, Peptides.
[142] D. Dickson,et al. Neuropathological Diagnosis of Alzheimer’s Disease: A Perspective from Longitudinal Clinicopathological Studies , 1997, Neurobiology of Aging.
[143] Allan I. Levey,et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.
[144] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[145] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[146] W. Powers,et al. Effect of stepped hypoglycemia on regional cerebral blood flow response to physiological brain activation. , 1996, The American journal of physiology.
[147] J. Rommens,et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.
[148] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[149] Donald W. Miller,et al. Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: Possible function in insulin processing in the blood–brain barrier , 1994, Journal of cellular physiology.
[150] C Cobelli,et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. , 1993, The Journal of clinical investigation.
[151] E. Ryding,et al. The influence of hypoglycaemia on regional cerebral blood flow and cerebral volume in Type 1 (insulin-dependent) diabetes mellitus , 1993, Diabetologia.
[152] C. Bucana,et al. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. , 1992, The American journal of pathology.
[153] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[154] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[155] J. Nalbantoglu,et al. Genetic Factors in Alzheimer's Disease , 1990, Journal of the American Geriatrics Society.
[156] R. Moxley,et al. Distribution of insulin receptor-like immunoreactivity in the rat forebrain , 1989, Neuroscience.
[157] P. Halban,et al. Intracellular pathways of insulin transport across vascular endothelial cells. , 1988, The American journal of physiology.
[158] W. Pardridge,et al. Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.
[159] W. Pardridge,et al. Receptor-mediated peptide transport through the blood-brain barrier. , 1986, Endocrine reviews.
[160] W. Pardridge,et al. Enhanced Insulin Binding to Blood-Brain Barrier In Vivo and to Brain Microvessels In Vitro in Newborn Rabbits , 1985, Diabetes.
[161] G. King,et al. Receptor-mediated transport of insulin across endothelial cells. , 1985, Science.
[162] M. Brownstein,et al. Identification of insulin in rat brain. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[163] H. Davson. Blood–brain barrier , 1977, Nature.
[164] M. Roth,et al. The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.
[165] R. U. Margolis,et al. Insulin in the Cerebrospinal Fluid , 1967, Nature.
[166] F. Calon,et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia. , 2015, Prostaglandins, leukotrienes, and essential fatty acids.
[167] B. de Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.
[168] Emily H. Trittschuh,et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. , 2015, Journal of Alzheimer's disease : JAD.
[169] Su Gao,et al. Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. , 2014, Neuro endocrinology letters.
[170] G. Pandini,et al. Insulin has multiple antiamyloidogenic effects on human neuronal cells. , 2013, Endocrinology.
[171] H. Fillit,et al. Beyond amyloid: the future of therapeutics for Alzheimer's disease. , 2012, Advances in pharmacology.
[172] F. Calon,et al. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. , 2012, Journal of Alzheimer's disease : JAD.
[173] W. Valentine,et al. Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. , 2011, Current diabetes reviews.
[174] E. Cornford,et al. Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy , 2011, NeuroRX.
[175] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[176] R. Deane,et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. , 2009, CNS & neurological disorders drug targets.
[177] R. Carare,et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.
[178] G. Schellenberg,et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.
[179] D. Bennett,et al. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.
[180] D. Bennett,et al. Biochemical Characterization of Aβ and Tau Pathologies in Mild Cognitive Impairment and Alzheimer's Disease , 2007 .
[181] J. Wands,et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.
[182] J. Hendrick,et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. , 2005, The Journal of pharmacology and experimental therapeutics.
[183] J. Pickard,et al. Symmetry of cerebral blood flow and cognitive responses to hypoglycaemia in humans , 2004, Diabetologia.
[184] S. Asthana,et al. Insulin increases CSF Abeta42 levels in normal older adults. , 2003, Neurology.
[185] Weiming Xia,et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.
[186] H. Braak,et al. Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.
[187] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.
[188] G. Gessa,et al. Possible role of insulin in the transport of tyrosine and tryptophan from blood to brain. , 1976, Advances in experimental medicine and biology.
[189] Justin Paul,et al. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease , 2007, The Journal of experimental medicine.